Assesses hydroxypropyl-β-cyclodextrin's impact on thalidomide stability and solubility in HIV-infected children, suggesting improved formulations.
The aim of this work was to study the effect of hydroxypropyl-β-cyclodextrin on the solubility and stability of thalidomide enantiomers in aqueous solutions for clinical oral administration to be used in HIV-infected children. For this reason racemic thalidomide was added to solutions containing different concentrations of hydroxypropyl-β-cyclodextrin. True complexes were obtained by using hydroxypropyl-β-cyclodextrin and the solubility of both thalidomide enantiomers was increased directly depending on the amount of hydroxylpropyl-β-cyclodextrin in the medium although no enantioselective differences were observed at 37 °C. The chemical stability of thalidomide enantiomers is clearly improved by hydroxypropyl-β-cyclodextrin. No enantioselective degradation of thalidomide was observed in sodium chloride solution (0.9%) samples stored at 6 °C for nine days when hydroxypropyl-β-cyclodextrin was employed as excipient. Therefore a thalidomide solution suitable for oral administration can be prepared by adding hydroxypropyl-β-cyclodextrin at 10% (w/v).
No takes yet. Share an insight, caveat, or question.
Álvarez et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: